|
N-(furan-2-ylmethylcarbamoyl)-2-(4-oxobenzo[g]quinazolin-3-yl)acetamide |
|
Shigella |
TTSS (Type III secretion system) |
Preclinical (in vivo) |
Case HB, et al. 2020. Biochemistry |
|
[2-[[(1R,2R)-2-methylcyclohexyl]carbamoylamino]-2-oxoethyl] 4-oxo-3-phenylphthalazine-1-carboxylate |
Depiction based on curated SMILES
N
N
O
O
N
H
H
H
H
3
C
O
N
H
O
O
|
Shigella |
TTSS (Type III secretion system) |
Preclinical (in vivo) |
Case HB, et al. 2020. Biochemistry |
|
2-phenyl-2,3-dihydrophthalazine-1,4-dione |
Depiction based on curated SMILES
O
O
N
HN
|
Shigella |
VirF |
Preclinical (in vitro) |
Hurt JK, et al. 2010. J Biomol Screen |
|
5-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-(ethylsulfonyl)-4-pyrimidinecarboxamide |
Depiction based on curated SMILES
N
H
Cl
N
S
CH
3
O
N
N
O
O
S
|
Shigella |
VirF |
Preclinical (in vitro) |
Emanuele AA, et al. 2014. J Antibiot (Tokyo); Emanuele AA, et al. 2015. PLoS One |
|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |